Alnylam Pharmaceuticals (BSP:A1LN34) Net Issuance of Preferred Stock : R$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Alnylam Pharmaceuticals's net issuance of preferred for the three months ended in Dec. 2023 was R$0 Mil. The number is 0, which means that Alnylam Pharmaceuticals has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Alnylam Pharmaceuticals's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was R$0 Mil.

Alnylam Pharmaceuticals Net Issuance of Preferred Stock Historical Data

The historical data trend for Alnylam Pharmaceuticals's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Net Issuance of Preferred Stock Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Alnylam Pharmaceuticals Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

Alnylam Pharmaceuticals Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines